Introduction
============

Primary open angle glaucoma (OAG) is a multifactorial optic neuropathy characterized by progressive retinal ganglion cell death and associated visual field loss. Glaucoma is the second leading cause of blindness worldwide ([@b77-co-2-849]), yet after years of extensive research the exact cause of glaucomatous optic neuropathy remains elusive. A recent estimate suggests that roughly 80 million people will be diagnosed with glaucoma by 2010, with 4.5 million of those suffering from bilateral blindness ([@b115-co-2-849]). Although elevated intraocular pressure (IOP) currently remains the focus of therapy, some glaucoma patients continue to experience disease progression despite lowering of IOP. The Early Manifest Glaucoma Trial (EMGT) showed that OAG disease progression rate in the treatment group was 45% as compared with 62% in the nontreated control group ([@b59-co-2-849]). In the Collaborative Initial Glaucoma Treatment Study (CIGTS), substantial visual field loss occurred in 10%--13.5% of participants during 5 years of follow up ([@b82-co-2-849]). Although IOP is still the only treatable OAG risk factor, it is clear that glaucoma is a complex disease that cannot be prevented or cured by IOP reducing therapies in all patients.

Other glaucoma risk factors that may be responsible for disease progression despite lowering of IOP include vascular risk factors, genetics, and other systemic conditions ([@b77-co-2-849]). Vascular related OAG risk factors have been found in prospective, retrospective, and large population-based studies throughout the world. While not a new concept ([@b134-co-2-849]; [@b54-co-2-849]; [@b57-co-2-849]; [@b32-co-2-849]), disturbed ocular blood flow has emerged as an increasingly prevalent glaucoma risk factor in large population-based trials. [@b78-co-2-849] recently presented new predictors of OAG disease progression in the EMGT trial including lower systolic perfusion pressure, lower systolic blood pressure, and cardiovascular disease history. In the Rotterdam eye study, patients with an ocular perfusion pressure lower than 50 mmHg had a four times greater risk of developing OAG than those with a perfusion pressure of 80 mmHg ([@b63-co-2-849]). The Egna-Neumarkt study found positive correlations between systemic blood pressure and both the diagnosis of OAG and elevated IOP ([@b8-co-2-849]). These large scale trials compliment various data from smaller prospective trials which have found aging, systemic blood pressure, nocturnal hypotension, ocular perfusion pressure, migraine, disk hemorrhage, diabetes, and directly assessed reductions of ocular blood flow to be related to OAG. It is currently unclear whether ischemia is secondary to increased IOP through faulty autoregulation of ocular blood flow or if a primary vascular component promotes damage to the optic nerve and retinal ganglion cells in certain OAG patients.

Recent studies have also suggested that perfusion instability, rather than a progressive decline in ocular blood flow, may contribute to OAG. It is well established that circadian rhythms play an important role in maintaining homeostasis in the human body. In that capacity, OAG progression is not necessarily related to the overall level of blood pressure, but an abnormal vascular reaction to a reduction in blood pressure or increase in IOP during nonwaking hours ([@b136-co-2-849]). It has been known for over four decades that IOP varies throughout the day, but not until recently has it been shown that other vascular risk factors such as systemic blood pressure ([@b100-co-2-849]), ocular perfusion pressure ([@b84-co-2-849]), and ocular blood flow ([@b109-co-2-849]) also follow circadian patterns. Ocular blood flow deficits may therefore represent either a primary insult or are secondary to vascular regulatory dysfunction during diurnal fluctuations in vascular risk factors in certain OAG patients ([@b43-co-2-849]).

Blood flow autoregulation in glaucoma
=====================================

Autoregulation of blood flow is described as the intrinsic capacity of an organ to maintain its blood flow despite changes in local vascular parameters ([@b47-co-2-849]). Within the eye, autoregulation is defined as local vascular constriction or dilation causing vascular resistance to reciprocally increase or decrease, thereby maintaining a constant nutrient supply in response to perfusion pressure changes ([@b51-co-2-849]). Challenges to normal ocular blood flow include increased IOP, fluctuating blood pressure, a resultant decrease in ocular perfusion pressure, and/or a rise in local tissue metabolic demands. Failure of stable blood flow regulation may lead to ischemic damage of the optic nerve and/or retinal ganglion cells, which likely contributes to further impairment in vascular regulation. A cascade of events may occur, which then leads to retinal ganglion cell death and structural changes of the optic nerve head (ONH) ([@b32-co-2-849]) consistent with OAG pathophysiology ([Figure 1](#f1-co-2-849){ref-type="fig"}).

Various underlying medical conditions have been proposed which may contribute to ocular vascular regulatory dysfunction including atherosclerosis, vasospasm, and endothelial dysfunction. This review highlights these and other factors as they relate to glaucomatous optic neuropathy and discusses potential implications in our understanding of OAG disease pathophysiology and management.

Physiology of the optic nerve head blood flow autoregulation
============================================================

The optic nerve is a continuation of the central nervous system and shares several physiologic similarities with the brain, including blood flow autoregulation ([@b30-co-2-849]). Despite extensive research, the precise microvascular anatomy and blood flow regulation of the ONH remains difficult to ascertain ([@b53-co-2-849]). Several mechanisms involved in the vascular regulation of ocular blood flow that have been demonstrated include: metabolic, myogenic, neurogenic, humoral, and endothelial-mediated factors.

Autoregulation of the cerebral circulation has been shown to depend largely on local blood gas perturbations ([@b47-co-2-849]). Similarly, as ONH blood flow decreases, the local metabolic vascular response is primarily oxygen-dependent ([@b73-co-2-849]). Hyperoxia and hypocapnia mediate arteriolar constriction and a subsequent decrease in ONH blood flow, while hypoxia and hypercapnia result in the opposite response ([@b30-co-2-849]). Additionally, the concentrations of K^+^, H^+^, adenosine, and intercellular osmolarity are known to influence local vascular tone ([@b104-co-2-849]).

Myogenic autoregulation involves arteriolar tone changes through smooth muscle cell to cell signal propagation ([@b64-co-2-849]). Specifically, transmural pressure sensitive arteriole pacemaker cells initiate the response and although the exact mechanism has not been defined, extracellular calcium concentrations and endothelial factors appear to contribute ([@b17-co-2-849]). While myogenic autoregulation contributes to a great extent in several organs, most notably the colonic vasculature ([@b2-co-2-849]), its role in ocular tissue is still under investigation.

The autonomic nervous system orchestrates a coordinated response to changes in systemic physiology. In the coronary circulation, for example, intrinsic cardiac and extracardiac autonomic neurons influence cardiac output and coronary blood flow, often irrespective of local stimuli ([@b74-co-2-849]). In ocular tissue, the autonomic nervous system contributes extensively to the retrobulbar and choroidal circulatory system, but the retinal and ONH vasculature lack direct innervation ([@b33-co-2-849]). Hence, sympathetic stimulation provides only indirect influence on OHN perfusion as neurogenic contribution to the vascular response is minimal ([@b53-co-2-849]).

In a prototypical vascular bed, vasoactive hormones in the circulating blood act directly on endothelial, pericyte, and smooth muscle cells. The ONH, however, is exceptional in that it contains 1) a blood -- brain barrier preventing smooth muscle and pericyte contact with humoral factors and 2) a scleral flange also acting as a barrier to prevent humoral diffusion from the choroid to the ONH ([@b30-co-2-849]). Hormones believed to exert an autoregulatory effect on the ONH by overcoming these barriers include circulating catecholamines ([@b143-co-2-849]), vasopressin, natriuretic peptides, and the renin -- angiotensin system ([@b66-co-2-849]).

The vascular endothelium directly regulates permeability, but also indirectly influences blood vessel diameter, coagulation parameters, cellular proliferation, and the inflammatory cascade amongst other pathways through the release of vasoactive susbstances ([@b4-co-2-849]). Endothelial mediators are increasingly reported factors in the regulation of ONH blood flow. Studies have demonstrated a basal formation of nitric oxide in the ocular endothelium that leads to active dilatation of the vasculature as well as a dose-dependent response relationship between endothelin-1 and blood flow to the anterior optic nerve, as discussed in detail later ([@b107-co-2-849]).

Atherosclerosis
===============

Atherosclerosis is a chronic, progressive disease affecting many vascular beds including the ocular circulation ([@b16-co-2-849]). It results from the deposition of lipids, inflammatory cells, and connective tissue within arterial walls, leading to plaque formation and intimal thickening. Over time this results in obstruction to flow, compromised perfusion, and tissue ischemia ([@b18-co-2-849]; [@b22-co-2-849]). Recent research on the topic of atherosclerosis has focused on molecular and cellular mechanisms and led to a shift in the paradigm of disease pathophysiology ([@b18-co-2-849]). Studies have shown endothelial cell dysfunction to be the first detectable change in atherosclerotic vessels ([@b4-co-2-849]). This is supported by the observation that risk factors such as aging, smoking, hypertension, elevated low-density lipoprotein (LDL) levels, diabetes, and ischemia have been shown to alter endothelial function ([@b85-co-2-849]). Both the barrier and secretory function of endothelial cells are perturbed in atherosclerosis, aiding in plaque formation. This also manifests as abnormal vasoreactivity in affected vessels, suggesting a predisposition to ischemic insult ([@b7-co-2-849]).

The current literature collectively demonstrates various mechanisms leading to autoregulatory dysfunction in atherosclerotic vessels. However, a corollary correlation between atherosclerosis and OAG has yet to be identified. The prospective Rotterdam eye study found neither atherosclerosis nor serum C-reactive protein (a marker of inflammation associated with atherosclerosis) to be important risk factors for the development of OAG ([@b22-co-2-849]). This is consistent with previous studies which were unable to find a significant relationship between atherosclerosis and OAG ([@b81-co-2-849]; [@b55-co-2-849]; [@b42-co-2-849]). Conversely, [@b56-co-2-849] noted that serotonin, a biomarker released during platelet aggregation on an atherosclerotic plaque, produced vasospasm of the central retinal and short posterior ciliary arteries in atherosclerotic monkeys. While lacking a control group and not performed in human subjects, Hayreh cites previous reports suggesting improvement of serotonin induced vasoconstriction after abstaining from an atherogenic diet for several months. Further, a recent study found over-expression of a specific subset of the phospholipase A2 enzyme family, a marker for atherosclerosis, in the ocular tissue of OAG patients ([@b117-co-2-849]). However, this result may point more to the role of oxidative stress than atherosclerosis in OAG disease pathogenesis.

It is important to note that noninvasive measurements of atherosclerosis are of limited utility. The methods used in previous studies included echography or radiography of the carotid arteries to quantify intimal thickness, abdominal imaging to measure calcification in the aorta and ankle-brachial index ([@b22-co-2-849]). These techniques are intended to provide in vivo quantification of systemic atherosclerosis, but measure only isolated vascular beds. Further, no study directly visualized the ocular circulation in humans, indicating a need for additional studies to accurately identify localized atherosclerosis and resulting changes in the vasculature of OAG patients.

Since atherosclerosis has a known association with other vascular risk factors such as aging, cerebrovascular and cardiovascular disease, several studies have attempted to discern a correlation between these factors and glaucoma. A recent report from the EMGT indicated cardiovascular disease history is a newly defined predictor of glaucomatous disease progression ([@b78-co-2-849]). As a systemic process, atherosclerosis plays a causative role in such pathology as myocardial infarction and cerebral vascular accidents. Several studies have reported an increased incidence of silent myocardial ischemia in glaucoma patients ([@b68-co-2-849]; [@b135-co-2-849]), while multiple reports link cerebral ischemia and infarct with glaucoma ([@b123-co-2-849]; [@b102-co-2-849]; [@b133-co-2-849]). Further, the incidence of OAG, atherosclerosis, and ocular ischemia are known to increase with age ([@b52-co-2-849]). With advancing age, there is a decrease in the relative capillary blood flow, velocity, and volume within the neuroretinal rim and lamina cribrosa of the ONH ([@b6-co-2-849]). Although multiple factors likely contribute to this process, it has been determined that retinal arteriolar and venular diameters narrow during normal aging due to age-associated vascular rigidity and atherosclerosis ([@b80-co-2-849]). This prevents the elderly population from having the same capacity to alter vessel diameter and thus blood flow as a function of autoregulation ([@b141-co-2-849]). This may help explain the observation that endothelial function of the retinal vasculature improves with angiotension AT1 receptor blockade in young patients, but shows no response in older individuals ([@b20-co-2-849]; [@b101-co-2-849]).

In summary, atherosclerosis has been demonstrated to cause autoregulatory dysfunction in multiple vascular beds resulting in significant vascular disease pathologies. Although a relationship between certain atherosclerotic risk factors and OAG has been reported, the direct influence of atherosclerosis on the progression of glaucoma is undetermined. More research is required to understand how atherosclerosis, cardiovascular disease, age, and blood flow autoregulation are inter-related in OAG disease pathophysiology.

Vasospasm
=========

Vasospasm is characterized as a sharp, exaggerated, and often persistent contraction of a blood vessel, resulting in a reduction in luminal diameter and respective blood flow ([@b86-co-2-849]). This vasoconstriction or insufficient dilatation of the microcirculation may lead to inadequate blood flow to the surrounding tissue and consequent ischemia. Simultaneous arterial or venous dilatations in neighboring vascular beds may be a by-product of vascular dysregulation in vasospastic individuals ([@b29-co-2-849]). Certain organs, such as the heart, brain, and eye produce clinically apparent spasms more regularly than other organ systems.

Vasospasm has been associated as a secondary finding in multiple disease states including multiple sclerosis, lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, giant cell arthritis, Behcet's disease, Crohn's disease, Buerger's disease, Raynaud's disease, prinzmetal's angina, preeclampsia, and AIDS ([@b40-co-2-849]; [@b32-co-2-849]). However, a primary vasospastic syndrome has also been discovered wherein patients without an underlying disease develop vasospasm in response to stimuli such as cold or emotional stress ([@b38-co-2-849]). This disorder is of particular interest since the most commonly reported organ involving vasospasm is the eye ([@b40-co-2-849]). This syndrome is found more frequently in women than men ([@b28-co-2-849]), which possibly correlates with the observation that normal tension glaucoma (NTG) is twice as common in women. Furthermore, the female gender is considered an independent risk factor for visual field loss progression in NTG ([@b103-co-2-849]; [@b25-co-2-849]). The increased susceptibility in females may be due to falling estrogen levels, which are known to have a vasoprotective effect and are reduced post-menopause ([@b121-co-2-849]). Similarly, vasospasm is also observed more commonly in Japanese than Caucasian patients and correspondingly, NTG is found more commonly in Japan than most other countries ([@b5-co-2-849]; [@b32-co-2-849]). These and various other studies suggest that vasospasm may exemplify a specific mechanism by which glaucomatous changes can occur ([@b68-co-2-849]; [@b96-co-2-849]; [@b42-co-2-849]; [@b3-co-2-849]; [@b32-co-2-849]). Vasospasm can create an environment of blood flow dysregulation which increases the vulnerability of the ONH to vascular challenges, leading to perfusion instability, ischemic changes, axonal loss, and changes of the ONH.

The most prevalent clinical signs and symptoms of vasospasm are cold hands and feet, low blood pressure, and migraine ([@b37-co-2-849], [@b42-co-2-849]; [@b38-co-2-849]; [@b105-co-2-849]; [@b32-co-2-849]). A systematic diagnosis of vasospasm syndrome has yet to be defined, but it has been suggested that finger or nail blood flow response to cold provocation can be diagnostic (Drance et al 1998; [@b41-co-2-849]). It is important to note that patients with glaucoma who have been shown to have evidence of vasospasm were more likely to demonstrate worsening of visual fields following cooling than nonvasospastic patients ([@b97-co-2-849]). This suggests that vasospasm may manifest itself in clinically relevant glaucomatous deterioration in certain individuals. Migraine, often characterized as a vasospastic disorder, is more commonly found in females and has a well documented association with NTG ([@b15-co-2-849]). It has been demonstrated as a risk factor for the progression of visual field loss, suggesting a common underlying vascular pathology for both conditions ([@b87-co-2-849]). Also frequently associated with vasospasm, low blood pressure is a reported risk factor for glaucoma, but if systemic hypotension is secondary to vasospasm or an unrelated phenomenon remains uncertain ([@b69-co-2-849]; [@b36-co-2-849]; [@b42-co-2-849]; [@b110-co-2-849]). It has been shown that blood pressure variations away from normal physiologic nocturnal dips are correlated with vasospasm, OAG, and NTG ([@b136-co-2-849]). The failure of ocular blood flow to remain constant during physiological challenges may manifest itself as ocular vasospasm or represent primary vascular dysregulation during vasospastic episodes.

Vasospasm is a transient phenomenon that is potentially reversible, allowing the restoration of steady-state perfusion. Due to its time-dependent nature, baseline blood flow measurements may not demonstrate any abnormalities compared with controls ([@b44-co-2-849]). Therefore, the use of a provocation test to unmask underlying vascular dysregulation has been proposed in ocular hemodynamic measurements ([@b45-co-2-849]). Studies have been conducted to demonstrate this reversibility. Increased visual field deficits have been demonstrated after cold water provocation in vasospastic patients that decreased with the administration of calcium channel blockers or magnesium ([@b38-co-2-849]; [@b39-co-2-849]; [@b35-co-2-849]). Likewise, treatment with calcium channel blockers has been shown to improve retrobulbar hemodynamics in some patients with NTG ([@b50-co-2-849]). In addition to calcium channel blockers, hyperoxia and elevated carbon dioxide (CO~2~) breathing are sometimes utilized to assess vascular reactivity. While studies investigating the retinal circulatory response to blood gas perturbations report conflicting results ([@b44-co-2-849]), reports consistently indicate CO~2~ inhalation provides a reversible improvement in visual field defects and a decrease in the resistive indices of orbital vessels ([@b137-co-2-849]; [@b98-co-2-849]). Specifically, [@b49-co-2-849] showed that NTG patients had significantly lower ophthalmic artery blood flow velocities and higher vascular resistance than controls. The differences between NTG and controls were reversed during elevated CO~2~ breathing, suggesting the presence of a reversible vasospasm in the NTG cohort ([@b49-co-2-849]). A study by [@b45-co-2-849] found women with vasospasm demonstrated an inverse response pattern of choroidal and ONH blood gas perturbations compared with women without vasospasm. The authors suggest that vasospastic patients may have diminished autoregulatory capacity or increased responsiveness to CO~2~ in certain vascular beds. A differentiation of normal and abnormal blood flow regulation during blood gas perturbations and calcium channel blockers may demonstrate which persons are at greatest risk for vasospasm, impaired ocular blood flow and possibly OAG.

The current body of literature suggests that vasospasm may play a more significant role in OAG ONH damage than atherosclerosis. Although both conditions have been shown to contribute to systemic autoregulatory dysfunction, it is hypothesized that most patients with increased vascular resistance secondary to atherosclerotic change compensate with proficient autoregulation in small arterioles and capillaries ([@b31-co-2-849]). Intracranial vessels seem more resistant to the development of atherosclerosis in comparison to other vascular beds ([@b27-co-2-849]). While effects of atherosclerosis are readily apparent on fundoscopic exam, relying on these changes for measure of systemic and retinal disease may be of limited utility ([@b60-co-2-849]). It is believed that perfusion fluctuates more dramatically in vasospastic patients, which can additionally lead to reperfusion damage ([@b119-co-2-849]).

The concept of vasospasm-induced reperfusion injury is heavily emphasized in other fields of research including vascular and transplant surgery ([@b65-co-2-849]), neurology ([@b116-co-2-849]), and cardiology ([@b75-co-2-849]). During myocardial ischemia and infarction, for example, reperfusion is characterized by the overproduction of oxygen-derived free radicals that spurn an acute inflammatory response and tissue degradation. It has also been argued that reperfusion injury alters the endothelium architecture, allowing for such adverse conditions as vasospasm and atherosclerosis to develop more readily ([@b75-co-2-849]).

In summary, vasospasm is associated with multiple disease states including OAG with NTG patients and women appearing to be the most at risk for vasopastic contributions to disease processes. Vasospasm may result in fluctuations in ocular perfusion, ischemia, and/or reperfusion injury to the ocular tissues. Importantly, vasospasm may be reversible (treatable). The capacity of diagnostic testing for OAG risk using blood gas perturbations should be further explored, especially in patients that demonstrate a vasospastic propensity.

Endothelial dysfunction
=======================

Endothelial dysfunction has been increasingly implicated in OAG disease pathophysiology. Disruption of the homeostatic factors maintaining physiologic vessel caliber may shift the balance toward an excess of vasoconstriction over vasodilation resulting in vasospasm ([@b19-co-2-849]). Similarly, atherosclerosis changes endothelial architecture and disrupts mechanisms contributing to endothelium-derived vascular relaxation ([@b27-co-2-849]). A causative and/or synergistic role involving atherosclerosis, vasospasm, and endothelial dysfunction may result in dysfunctional regulation of the ocular vasculature potentially contributing to OAG pathophysiology.

The vascular endothelium regulates the microcirculation through release of vasoactive factors, the most potent of which are the vasodilator nitric oxide (NO) and the vasoconstrictor endothelin-1 (ET-1) ([@b1-co-2-849]). Additional endothelium-derived activating compounds include prostacyclins, acetylcholine, bradykinin, and histamine ([@b30-co-2-849]; [@b1-co-2-849]). In endothelial cells, NO synthase (NOS) catalyzes the conversion of L-arginine to NO and L-citrulline. NO released from endothelial cells directly stimulates the surrounding vascular smooth muscle to promote vasodilation ([@b128-co-2-849]). Systemic factors such as hyperlipidemia, atherosclerosis, and hyperglycemia impair endothelial NO signaling through oxidative stress damage ([@b92-co-2-849]). Plasma levels of asymmetric dimethylarginine, an endogenous inhibitor of NOS, are disproportionately elevated in hyperlipidemia, hyperhomocystinemia, atherosclerosis, coronary artery disease, hyperglycemia, and other disorders affected by endothelial dysfunction ([@b91-co-2-849]; [@b19-co-2-849]). Conversely, infusions of L-arginine, a precursor molecule to NO, limit injury from ischemia, and reperfusion-induced endothelial dysfunction ([@b111-co-2-849]).

It is known that NO activity contributes to ocular auto-regulation and can protect the endothelium and nerve fiber layer against pathologic stressors implicated in glaucoma, ischemia, and diabetes ([@b128-co-2-849]). A recent report by [@b114-co-2-849] presents the first in vivo evidence for altered ocular L-arginine/NO pathway in glaucoma patients. Polymorphisms in the endothelium specific NOS (eNOS) have been found in familial patients with glaucoma ([@b132-co-2-849]). A preliminary study by Wiggs and colleagues also suggests the presence of a polymorphism in the eNOS gene in patients with high and NTG that predisposes these patients to superior paracentral field loss ([@b19-co-2-849]). Decreased levels of cyclic GMP, an indicator of NO activity, have been demonstrated in the plasma and aqueous humor of glaucoma patients, with corresponding lower systolic and diastolic ophthalmic artery blood flow velocities of NTG patients ([@b75-co-2-849]).

Opposing the vasodilation properties of NO is ET-1, the most important and potent vascular constricting factor. The peptide is synthesized by endothelial cells and either binds to the ET~A~ receptor on smooth muscle cells to mediate vasoconstriction or binds to the ET~B~ receptor on endothelial cells to mediate vasodilation via the autocrine release of NO, prostacyclin and by increasing removal of endothelin from the circulation. ([Figure 2](#f2-co-2-849){ref-type="fig"}) Although this indicates ET-1 can stimulate either vasoconstriction or vasodilation, the overall response in vivo is sustained and powerful vasoconstriction ([@b118-co-2-849]). There is evidence that enhanced ET-1 vasoconstriction is involved in the pathology of such conditions as hypertension, heart failure, myocardial infarction, renal failure, and secondary vasospastic disorders ([@b108-co-2-849]).

A number of studies have investigated the role of ET-1 in glaucoma. ET-1 has been shown to decrease blood flow to the anterior optic nerve when directly applied to this region ([@b106-co-2-849]). It has been determined that ET-1 provokes forceful contractions of isolated ophthalmic arteries with smaller vessels expressing greater ET-1 sensitivity ([@b46-co-2-849]; [@b113-co-2-849]). Utilizing arteries dissected from gluteal fat biopsies, [@b11-co-2-849] identified dysfunction of the systemic vascular endothelial cell in patients with NTG by demonstrating decreased responsiveness to ET-1 stimulation. Alterations in the vascular responsiveness to ET-1 or changes in synthesis, activation, and removal of the molecule may therefore result in impaired regulation of ocular blood flow. Several studies have demonstrated increased plasma ET-1 levels in NTG patients ([@b124-co-2-849]; [@b70-co-2-849]), but these results have not been reproduced in patients with high tension glaucoma (HTG) ([@b126-co-2-849]). Aqueous humor levels of ET-1 are reportedly elevated in HTG ([@b99-co-2-849]) and one study demonstrated a significant elevation of plasma ET-1 in HTG when the subjects were moved from the supine to upright position (Kaiser et al 1997). To further support a role for vasospasm in endothelial dysfunction, [@b97-co-2-849] reported an abnormal increase in plasma ET-1 in response to body cooling in OAG patients. This suggests a hyperactive production and/or release of ET-1 in response to vasospastic stimuli in predisposed patients ([@b97-co-2-849]).

Several recent studies have shifted the focus from solely examining ET-1 expression to investigating the role of ET~A~ and ET~B~ receptors in ocular blood flow. In studies of porcine eyes, ET-1 increases ocular blood flow at negligible doses and reduces it at higher ones, which is thought to occur secondary to activation of ET~B~ and ET~A~ receptors, respectively ([@b142-co-2-849]). This suggests that low ET-1 doses have a greater affinity for ET~B~ receptors to cause vasodilation, but increased levels of ET-1 leads to vasoconstriction by binding to ET~A~ receptors. Blocking ET~A~ receptors to the exogenous administration of ET-1 in humans has been shown to reverse the observed reduction in retinal blood flow, further indicating that ET~A~ receptors mediate the vasoconstrictive effects of ET-1 in the retina ([@b124-co-2-849]). In patients with NTG, Henry et al reported normal vasoreactivity to ET-1, but significantly decreased vasodilation in response to ET~A~ receptor antagonism. The authors suggest this response may be due to a combination of diminished ET~A~ receptor-mediated tone, increased ET~B~ receptor mediated contraction, or impaired release of NO ([@b61-co-2-849]). Correspondingly, polymorphisms of the ET~A~ receptor have been associated with NTG ([@b72-co-2-849]).

ET~B~ receptor polymorphisms, however, have yet to show any significant association with systemic or ocular disease ([@b19-co-2-849]). The role of ET~B~ in vascular physiology is shown to be selectively dependent on the tissue bed. It has been demonstrated in both rat and monkey models of sub-arachnoid hemorrhage that increased smooth muscle cell ET~B~ receptor expression induces vasospasm of cerebral vessels ([@b62-co-2-849]; [@b48-co-2-849]). Conversely, the function of ET~B~ in human skin seems insignificant ([@b83-co-2-849]). The role of ET~B~ in ocular hemodynamics is yet to be determined, but similar to other vascular beds in the body, it is likely influenced by the proportion of endothelial to smooth muscle cells and corresponding ET~A~/ET~B~ ratio ([@b19-co-2-849]).

In addition to directly reducing ocular blood flow, ET-1 increases local vascular sensitivity to other vasoconstrictive elements such as angiotensin II and catecholamines ([@b120-co-2-849]). [@b43-co-2-849] suggest that the elevation of ET-1 in glaucoma represents an epiphenomenon rather than a distinctive mechanism. They point to the observation of significantly elevated ET-1 levels in vasospastic and systemic diseases such as multiple sclerosis, rheumatoid arthritis, fibromyalgia, and Susac syndrome. Although a pale ONH is often associated with these diseases, glaucoma does not occur more frequently in these patients than in the average population. This suggests that ET-1 upregulation may be secondary to repetitive perfusion insufficiency and damage occurring not only in the ONH, but also subclinically in multiple organs ([@b135-co-2-849]; [@b43-co-2-849]). Although animal models have suggested that increased levels of ET-1 by itself can lead to glaucoma via ischemia ([@b14-co-2-849]), these same results have not been demonstrated in human population studies.

In summary endothelial dysfunction is likely related to glaucoma, but the exact role of mediators such as NO, NOS, ET-1, and ET~A~/ET~B~ in OAG pathophysiology has yet to be fully appreciated. Endothelial dysfunction may therefore be primary or secondary to vascular diseases including atherosclerosis and vasospasm in its contribution to OAG pathology.

Blood pressure changes and blood flow
=====================================

Fluctuations in IOP, blood pressure, ocular perfusion pressure, and thus blood flow are implicated in OAG. A patient with vasospastic syndrome may not be able to compensate for elevations of IOP and/or blood pressure dips, while a healthy patient can autoregulate to maintain consistent ocular perfusion. While not detailed in this review, several studies have found a modest association between OAG and hypertension ([@b127-co-2-849]; [@b8-co-2-849]; [@b90-co-2-849]), while others found no significant relationships ([@b76-co-2-849], [@b79-co-2-849]). [@b13-co-2-849] investigated 24-hour IOP, blood pressure, and perfusion pressure changes associated with clinically relevant visual field outcomes. The study determined that both anatomic (retinal nerve fiber layer thickness) and functional (visual field) outcome variables were significantly worse in glaucoma patients with wider circadian perfusion pressure fluctuations. The authors attributed glaucoma progression to daily repetitive ischemic insults followed by reperfusion injury in eyes through dysfunctional regulation mechanisms that could not maintain consistent perfusion pressure ([@b13-co-2-849]). In the Thessaloniki Eye Study, patients without glaucoma having a diastolic blood pressure of \<90 mm Hg with antihypertensive treatment was associated with increased cupping and decreased rim area of the optic disk ([@b129-co-2-849]). A recent report from the European Glaucoma Prevention Study (EGPS) indicates that systemic diuretic use was associated with the development of OAG ([@b89-co-2-849]). This may be due to the inability of the eye to maintain consistent, adequate perfusion during pharmacologically lowered blood pressure in susceptible individuals. A detailed review of fluctuations in blood pressure, IOP, ocular perfusion pressure and blood flow are covered in great detail elsewhere ([@b136-co-2-849]).

Diabetes and glaucoma
=====================

Other vascular diseases, such as diabetes, have conflicting reports about a potential role in OAG pathology ([@b78-co-2-849]), although a significant correlation with diabetes was determined by a meta-analysis ([@b9-co-2-849]). Diabetes, a disease with many vascular complications, has been reported to be related to glaucoma, however the evidence for diabetes as a contributing factor in OAG pathology is currently lacking. Population-based studies, such as the Baltimore eye survey, the Barbados eye study, and the Rotterdam study failed to support an association between diabetes and glaucoma. The relationship with other vascular risk factors are even less well defined, with a previous review indicating no consensus between OAG and smoking, hypercholesterolemia, or body mass index ([@b31-co-2-849]).

The role of other vascular diseases in glaucoma remains unclear. How each disease is related to ocular vascular regulation, or lack thereof, is uncertain. It is possible that understanding how OAG patients react differently to physiological challenges than healthy controls may reveal the differences reported in the literature. It is also possible that diabetes and hypercholesterolemia, while vascular in nature, do not directly influence ocular vascular regulation in a capacity that contributes to OAG.

Clinical and therapeutic implications
=====================================

With evidence supporting vascular risk factors in glaucomatous optic neuropathy, the medical community may choose to modify the focus of OAG disease characterization and management. Certain patients with glaucoma demonstrate vascular regulatory dysfunction. Physiologic phenomenons, such as circadian variations of IOP, ocular perfusion pressure, and ocular blood flow are generating increasing evidence for their role in ocular ischemia and OAG disease processes ([@b136-co-2-849]). Systemic medications such as antihypertensives have been shown to exacerbate OAG changes, indicating a need for heightened awareness of medication regimens in the glaucoma patient population ([@b93-co-2-849]).

To screen for a primary vasospastic disorder, a recent review recommends practitioners include questions regarding a history of cold hands/feet, migraine or hypotension in patients ([@b19-co-2-849]). A thorough assessment of vascular risk factors including a history of cardiovascular disease may assist in predicting disease progression and in improving management in identified patients ([@b78-co-2-849]).

Several vascular pharmacological targets have been identified in preliminary therapeutic trials for vascular dysfunctional regulation. Calcium channel blockers have been shown to improve outcomes in vasospastic-induced secondary ischemia in patients with subarachnoid hemorrhage ([@b88-co-2-849]) and intractable migraine ([@b95-co-2-849]). Authors have demonstrated calcium channel blocker-induced relief of coronary spasm following coronary artery bypass grafting ([@b12-co-2-849]), with one study suggesting injection of calcium blockers whenever there is reason to suspect vasospasm in arterial grafts ([@b58-co-2-849]). In ocular ischemia, calcium channel antagonists can be indicated in the treatment of the ocular ischemia syndrome and amaurosis fugax ([@b138-co-2-849]; [@b139-co-2-849]). Similarly, calcium channel blockers may reduce ocular vasospasm in certain glaucoma patients ([@b50-co-2-849]; [@b31-co-2-849]). Several studies show that calcium channel antagonists reduce the effect of increased levels of ET-1 on ocular perfusion and improve visual field defects through induced vasodilation ([@b32-co-2-849]). Magnesium also reduces ET-1-induced vasospasm and although it is actively being pursued in the management of subarachnoid hemorrhage, its usefulness in glaucoma is currently unknown ([@b21-co-2-849]; [@b88-co-2-849]). Blood gas changes, including elevated CO~2~ breathing may also be used to test for vasospastic tendency and/or reversibility ([@b49-co-2-849]).

The contribution of NO in the treatment of vascular dysfunctional regulation is becoming increasingly apparent. Investigations into cerebral vasospasm following cerebral vascular insults have demonstrated reduced vasospasm and ischemia-reperfusion injury with nitrate infusion ([@b112-co-2-849]; [@b67-co-2-849]). The stroke literature has recently highlighted a role for initiating or continuing statin therapy in patients with vasospasm and ischemia-reperfusion injury ([@b26-co-2-849]; [@b130-co-2-849]). These medications are thought to produce a local effect through upregulation and activation of eNOS to increase NO production ([@b131-co-2-849]). NO has also been shown to protect the liver and heart against reperfusion injury, with one report suggesting a role for daily dietary nitrite and nitrate therapy for optimal cardiovascular health ([@b10-co-2-849]). Studies concerning ocular health have demonstrated that systemic nitroglycerin preparations have a protective effect against optic neuropathy in glaucoma patients taking the medication for nonophthalmic reasons ([@b144-co-2-849]). Acute intravenous and oral administration of nitroglycerine lowers IOP in both glaucoma and healthy patients, with a transient increase in ocular blood flow ([@b140-co-2-849]; [@b122-co-2-849]). The L-arginine/NO/cyclic GMP pathway has also been implicated in the IOP decrease ([@b71-co-2-849]). Chronic exposure to NO may actually contribute to glaucomatous progression ([@b128-co-2-849]), indicating a potential role for NOS inhibition or a potential for downregulation or insensitivity. For example, inducible NOS (iNOS) is expressed only during inflammation and other pathological responses resulting in abundant NO production and eventual retinal ganglion cell loss ([@b128-co-2-849]). Animal trials of iNOS selective inhibition have demonstrated significantly lower retinal ganglion cell loss in treated versus untreated subjects ([@b94-co-2-849]). It is therefore recommended that future efforts continue to elucidate the role of NO and its use in potential therapeutic interventions.

In a similar fashion, the known effect of endothelin on systemic and ocular circulation has led to a number of studies investigating potential therapeutic strategies. The pharmaceutical industry has recognized the importance of this biomolecule and an increasing number of ET~A~ specific antagonists are undergoing trials for the management of hypertension ([@b23-co-2-849]). Preliminary studies also suggest this selective antagonism maintains endothelin's role in vascular relaxation ([@b125-co-2-849]). Endothelin mediated pathology has been demonstrated in the ocular circulation, although application of this knowledge to disease therapy is currently limited.

Conclusion
==========

Glaucoma is a comprehensive term for a heterogeneous disease comprising multiple etiologies. Alterations in ocular blood flow have become increasingly implicated in OAG disease pathology. The current body of literature suggests several possible mechanisms may be involved in the vascular regulatory dysfunction of OAG patients, although an inclusive appreciation from the molecular level to the clinically apparent is incomplete. Generalized vascular diseases, including endothelial dysfunction, atherosclerosis, and vasospasm may contribute to OAG disease pathophysiology. Patients suffering from vascular impairment, and therefore, faulty regulation of blood flow may be unable to compensate for physiologic fluctuations in IOP and blood pressure to maintain ocular perfusion pressures. This may result in chronic, intermittent ischemic and reperfusion damage to the ONH, which contributes to glaucomatous optic neuropathy. Continuing research is needed to discern the significance of the vascular factors presented in this text, along with others not mentioned or unknown. Long-term multicenter clinical trials investigating the relationship between vascular dysregulation in glaucoma patients and nonclinical outcomes such as visual function and optic nerve changes are necessary.
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